These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34440097)

  • 1. HOXB5 Overexpression Is Associated with Neuroendocrine Differentiation and Poor Prognosis in Prostate Cancer.
    Sekino Y; Pham QT; Kobatake K; Kitano H; Ikeda K; Goto K; Inoue S; Hayashi T; Shiota M; Yasui W; Teishima J
    Biomedicines; 2021 Jul; 9(8):. PubMed ID: 34440097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HOXB5 Promotes the Proliferation and Invasion of Breast Cancer Cells.
    Lee JY; Hur H; Yun HJ; Kim Y; Yang S; Kim SI; Kim MH
    Int J Biol Sci; 2015; 11(6):701-11. PubMed ID: 25999793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCL12-mediated HOXB5 overexpression facilitates Colorectal Cancer metastasis through transactivating CXCR4 and ITGB3.
    Feng W; Huang W; Chen J; Qiao C; Liu D; Ji X; Xie M; Zhang T; Wang Y; Sun M; Tian D; Fan D; Nie Y; Wu K; Xia L
    Theranostics; 2021; 11(6):2612-2633. PubMed ID: 33456563
    [No Abstract]   [Full Text] [Related]  

  • 4. Homeobox B5 promotes metastasis and poor prognosis in Hepatocellular Carcinoma, via FGFR4 and CXCL1 upregulation.
    He Q; Huang W; Liu D; Zhang T; Wang Y; Ji X; Xie M; Sun M; Tian D; Liu M; Xia L
    Theranostics; 2021; 11(12):5759-5777. PubMed ID: 33897880
    [No Abstract]   [Full Text] [Related]  

  • 5. HOXB5 promotes malignant progression in pancreatic cancer via the miR-6732 pathway.
    Li ZX; Wu G; Jiang WJ; Li J; Wang YY; Ju XM; Yin YT
    Cell Cycle; 2020 Jan; 19(2):233-245. PubMed ID: 31876226
    [No Abstract]   [Full Text] [Related]  

  • 6. The Calcium-Sensing Receptor is A Marker and Potential Driver of Neuroendocrine Differentiation in Prostate Cancer.
    Bery F; Cancel M; Chantôme A; Guibon R; Bruyère F; Rozet F; Mahéo K; Fromont G
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32252342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HOXB5 acts as an oncogenic driver in head and neck squamous cell carcinoma via EGFR/Akt/Wnt/β-catenin signaling axis.
    Lee K; Chang JW; Oh C; Liu L; Jung SN; Won HR; Kim YI; Rha KS; Koo BS
    Eur J Surg Oncol; 2020 Jun; 46(6):1066-1073. PubMed ID: 31864826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional activation of EGFR by HOXB5 and its role in breast cancer cell invasion.
    Lee JY; Kim JM; Jeong DS; Kim MH
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2924-2930. PubMed ID: 30115380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HOXB5 promotes proliferation, migration, and invasion of pancreatic cancer cell through the activation of the GSK3β/β-catenin pathway.
    Gao Y; Fei X; Kong L; Tan X
    Anticancer Drugs; 2020 Sep; 31(8):828-835. PubMed ID: 32796404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of Pleomorphic Adenoma Gene-Like 2 Is a Novel Poor Prognostic Marker of Prostate Cancer.
    Guo J; Wang M; Wang Z; Liu X
    PLoS One; 2016; 11(8):e0158667. PubMed ID: 27537362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The SOX4/miR-17-92/RB1 Axis Promotes Prostate Cancer Progression.
    Liu H; Wu Z; Zhou H; Cai W; Li X; Hu J; Gao L; Feng T; Wang L; Peng X; Qi M; Liu L; Han B
    Neoplasia; 2019 Aug; 21(8):765-776. PubMed ID: 31238254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of Homeobox B5 (HOXB5) Inhibits Cell Proliferation, Migration, and Invasion in Non-Small Cell Lung Cancer Cells Through Inactivation of the Wnt/β-Catenin Pathway.
    Zhang B; Li N; Zhang H
    Oncol Res; 2018 Jan; 26(1):37-44. PubMed ID: 28337958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
    Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
    Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting RET Kinase in Neuroendocrine Prostate Cancer.
    VanDeusen HR; Ramroop JR; Morel KL; Bae SY; Sheahan AV; Sychev Z; Lau NA; Cheng LC; Tan VM; Li Z; Petersen A; Lee JK; Park JW; Yang R; Hwang JH; Coleman I; Witte ON; Morrissey C; Corey E; Nelson PS; Ellis L; Drake JM
    Mol Cancer Res; 2020 Aug; 18(8):1176-1188. PubMed ID: 32461304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HOXB5 promotes retinoblastoma cell migration and invasion via ERK1/2 pathway-mediated MMPs production.
    Xu H; Zhao H; Yu J
    Am J Transl Res; 2018; 10(6):1703-1712. PubMed ID: 30018711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.
    Gururajan M; Cavassani KA; Sievert M; Duan P; Lichterman J; Huang JM; Smith B; You S; Nandana S; Chu GC; Mink S; Josson S; Liu C; Morello M; Jones LW; Kim J; Freeman MR; Bhowmick N; Zhau HE; Chung LW; Posadas EM
    Oncotarget; 2015 Dec; 6(42):44072-83. PubMed ID: 26624980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevation of androgen receptor promotes prostate cancer metastasis by induction of epithelial-mesenchymal transition and reduction of KAT5.
    Lin CY; Jan YJ; Kuo LK; Wang BJ; Huo C; Jiang SS; Chen SC; Kuo YY; Chang CR; Chuu CP
    Cancer Sci; 2018 Nov; 109(11):3564-3574. PubMed ID: 30142696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzalutamide-Induced Upregulation of PCAT6 Promotes Prostate Cancer Neuroendocrine Differentiation by Regulating miR-326/HNRNPA2B1 Axis.
    Liu B; Jiang HY; Yuan T; Luo J; Zhou WD; Jiang QQ; Wu D
    Front Oncol; 2021; 11():650054. PubMed ID: 34277403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.
    Flores-Morales A; Bergmann TB; Lavallee C; Batth TS; Lin D; Lerdrup M; Friis S; Bartels A; Kristensen G; Krzyzanowska A; Xue H; Fazli L; Hansen KH; Røder MA; Brasso K; Moreira JM; Bjartell A; Wang Y; Olsen JV; Collins CC; Iglesias-Gato D
    Clin Cancer Res; 2019 Jan; 25(2):595-608. PubMed ID: 30274982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
    Wang J; Xu W; Mierxiati A; Huang Y; Wei Y; Lin G; Dai B; Freedland SJ; Qin X; Zhu Y; Ye DW
    Prostate; 2019 Sep; 79(13):1563-1571. PubMed ID: 31376193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.